The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1

PLoS Pathogens

Volumn 8, Issue 2, 2012, Pages

  Robinson, Amanda R ^a,b   Kwek, Swee Sen ^a   Kenney, Shannon C ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMEDIATE EARLY PROTEIN BZLF1; OCTAMER TRANSCRIPTION FACTOR 2; SHORT HAIRPIN RNA;

ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DIMERIZATION; DNA BINDING; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOBLASTOID CELL; NASOPHARYNX CARCINOMA; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; VIRUS GENE; VIRUS LATENCY; VIRUS REACTIVATION;

B-CELL-SPECIFIC ACTIVATOR PROTEIN; B-LYMPHOCYTES; CELL LINE, TUMOR; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, VIRAL; GENE KNOCKDOWN TECHNIQUES; HERPESVIRUS 4, HUMAN; HUMANS; OCTAMER TRANSCRIPTION FACTOR-2; PROMOTER REGIONS, GENETIC; PROTEIN MULTIMERIZATION; TRANS-ACTIVATORS; VIRUS ACTIVATION; VIRUS LATENCY;

HUMAN HERPESVIRUS 4;

EID: 84860904972     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002516     Document Type: Article

References (94)

1. Kieff E, Rickinson AB, (2007) Epstein-Barr virus and its replication. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, editors. Fields Virology. 5th ed. ed Philadelphia, PA Lippincott Williams & Wilkins pp. 2603-2654.
2. Rickinson AB, Kieff E, (2006) Epstein-Barr virus. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, editors. Fields Virology. 5th ed. ed Philadelphia, PA Lippincott Williams & Wilkins pp. 2655-2700.
3. zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, et al. (1970) EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228: 1056-1058.
4. Souza TA, Stollar BD, Sullivan JL, Luzuriaga K, Thorley-Lawson DA, (2005) Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proc Natl Acad Sci U S A 102: 18093-18098.
5. Greenspan JS, Greenspan D, Lennette ET, Abrams DI, Conant MA, et al. (1985) Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N Engl J Med 313: 1564-1571.
6. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA, (1998) EBV persistence in memory B cells in vivo. Immunity 9: 395-404.
7. Webster-Cyriaque J, Middeldorp J, Raab-Traub N, (2000) Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections. J Virol 74: 7610-7618.
8. Walling DM, Flaitz CM, Nichols CM, Hudnall SD, Adler-Storthz K, (2001) Persistent productive Epstein-Barr virus replication in normal epithelial cells in vivo. J Infect Dis 184: 1499-1507.
9. Laichalk LL, Thorley-Lawson DA, (2005) Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 79: 1296-1307.
10. Rooney CM, Gregory CD, Rowe M, Finerty S, Edwards C, et al. (1986) Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines. J Natl Cancer Inst 77: 681-687.
11. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, et al. (1987) Differences in B-cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 6: 2743-2751.
12. Speck SH, (2005) Regulation of EBV Latency-Associated Gene Expression. In: Robertson ES, editors. Epstein-Barr Virus England Caister Academic Press pp. 403-427.
13. Chevallier-Greco A, Manet E, Chavrier P, Mosnier C, Daillie J, et al. (1986) Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter. EMBO J 5: 3243-3249.
14. Countryman J, Jenson H, Seibl R, Wolf H, Miller G, (1987) Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol 61: 3672-3679.
15. Countryman J, Miller G, (1985) Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A 82: 4085-4089.
16. Ragoczy T, Heston L, Miller G, (1998) The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol 72: 7978-7984.
17. Takada K, Shimizu N, Sakuma S, Ono Y, (1986) trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J Virol 57: 1016-1022.
18. Zalani S, Holley-Guthrie E, Kenney S, (1996) Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc Natl Acad Sci U S A 93: 9194-9199.
19. Rooney CM, Rowe DT, Ragot T, Farrell PJ, (1989) The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J Virol 63: 3109-3116.
20. Adamson AL, Darr D, Holley-Guthrie E, Johnson RA, Mauser A, et al. (2000) Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol 74: 1224-1233.
21. Feederle R, Kost M, Baumann M, Janz A, Drouet E, et al. (2000) The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 19: 3080-3089.
22. Liu P, Speck SH, (2003) Synergistic autoactivation of the Epstein-Barr virus immediate-early BRLF1 promoter by Rta and Zta. Virology 310: 199-206.
23. Flemington E, Speck SH, (1990) Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol 64: 1227-1232.
24. Binné UK, Amon W, Farrell PJ, (2002) Promoter sequences required for reactivation of Epstein-Barr virus from latency. J Virol 76: 10282-10289.
25. Bhende PM, Seaman WT, Delecluse HJ, Kenney SC, (2004) The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nat Genet 36: 1099-1104.
26. Lieberman PM, Hardwick JM, Sample J, Hayward GS, Hayward SD, (1990) The zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions. J Virol 64: 1143-1155.
27. Dickerson SJ, Xing Y, Robinson AR, Seaman WT, Gruffat H, et al. (2009) Methylation-dependent binding of the epstein-barr virus BZLF1 protein to viral promoters. PLoS Pathog 5: e1000356.
28. Kalla M, Schmeinck A, Bergbauer M, Pich D, Hammerschmidt W, (2010) AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc Natl Acad Sci U S A 107: 850-855.
29. Chen LW, Chang PJ, Delecluse HJ, Miller G, (2005) Marked variation in response of consensus binding elements for the Rta protein of Epstein-Barr virus. J Virol 79: 9635-9650.
30. Quinlivan EB, Holley-Guthrie EA, Norris M, Gutsch D, Bachenheimer SL, et al. (1993) Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res 21: 1999-2007.
31. Gruffat H, Sergeant A, (1994) Characterization of the DNA-binding site repertoire for the Epstein-Barr virus transcription factor R. Nucleic Acids Res 22: 1172-1178.
32. Gruffat H, Duran N, Buisson M, Wild F, Buckland R, et al. (1992) Characterization of an R-binding site mediating the R-induced activation of the Epstein-Barr virus BMLF1 promoter. J Virol 66: 46-52.
33. Gruffat H, Manet E, Rigolet A, Sergeant A, (1990) The enhancer factor R of Epstein-Barr virus (EBV) is a sequence-specific DNA binding protein. Nucleic Acids Res 18: 6835-6843.
34. Adamson AL, Kenney SC, (1998) Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product. Virology 251: 187-197.
35. Cox MA, Leahy J, Hardwick JM, (1990) An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators. J Virol 64: 313-321.
36. Chang LK, Chuang JY, Nakao M, Liu ST, (2010) MCAF1 and synergistic activation of the transcription of Epstein-Barr virus lytic genes by Rta and Zta. Nucleic Acids Res 38: 4687-4700.
37. Farrell PJ, Rowe DT, Rooney CM, Kouzarides T, (1989) Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J 8: 127-132.
38. Hardwick JM, Lieberman PM, Hayward SD, (1988) A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol 62: 2274-2284.
39. Kenney S, Kamine J, Holley-Guthrie E, Lin JC, Mar EC, et al. (1989) The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J Virol 63: 1729-1736.
40. Ellis AL, Wang Z, Yu X, Mertz JE, (2010) Either ZEB1 or ZEB2/SIP1 can play a central role in regulating the Epstein-Barr virus latent-lytic switch in a cell-type-specific manner. J Virol 84: 6139-6152.
41. Yu X, Wang Z, Mertz JE, (2007) ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus. PLoS Pathog 3: e194.
42. Kraus RJ, Perrigoue JG, Mertz JE, (2003) ZEB negatively regulates the lytic-switch BZLF1 gene promoter of Epstein-Barr virus. J Virol 77: 199-207.
43. Feng WH, Kraus RJ, Dickerson SJ, Lim HJ, Jones RJ, et al. (2007) ZEB1 and c-Jun levels contribute to the establishment of highly lytic Epstein-Barr virus infection in gastric AGS cells. J Virol 81: 10113-10122.
44. Bhende PM, Dickerson SJ, Sun X, Feng WH, Kenney SC, (2007) X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D. J Virol 81: 7363-7370.
45. Sun CC, Thorley-Lawson DA, (2007) Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter. J Virol 81: 13566-13577.
46. Bryant H, Farrell PJ, (2002) Signal Transduction and Transcription Factor Modification during Reactivation of Epstein-Barr Virus from Latency. J Virol 76: 10290-10298.
47. Iempridee T, Das S, Xu I, Mertz JE, (2011) Transforming growth factor beta-induced reactivation of Epstein-Barr virus involves multiple Smad-binding elements cooperatively activating expression of the latent-lytic switch BZLF1 gene. J Virol 85: 7836-7848.
48. Swenson JJ, Holley-Guthrie E, Kenney SC, (2001) Epstein-Barr virus immediate-early protein BRLF1 interacts with CBP, promoting enhanced BRLF1 transactivation. J Virol 75: 6228-6234.
49. Adamson AL, Kenney S, (1999) The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein. J Virol 73: 6551-6558.
50. Adamson AL, Kenney S, (2001) Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J Virol 75: 2388-2399.
51. Gutsch DE, Holley-Guthrie EA, Zhang Q, Stein B, Blanar MA, et al. (1994) The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B. Mol Cell Biol 14: 1939-1948.
52. Zhang Q, Gutsch D, Kenney S, (1994) Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol Cell Biol 14: 1929-1938.
53. Mauser A, Saito S, Appella E, Anderson CW, Seaman WT, et al. (2002) The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J Virol 76: 12503-12512.
54. Murata T, Sato Y, Nakayama S, Kudoh A, Iwahori S, et al. (2009) TORC2, a coactivator of cAMP-response element-binding protein, promotes Epstein-Barr virus reactivation from latency through interaction with viral BZLF1 protein. J Biol Chem 284: 8033-8041.
55. Robinson AR, Kwek SS, Hagemeier SR, Wille CK, Kenney SC, (2011) The Cellular Transcription Factor, Oct-1, Interacts with the Epstein-Barr Virus BRLF1 Protein to Promote Disruption of Viral Latency. J Virol 85: 8940-53.
56. Kang J, Shakya A, Tantin D, (2009) Stem cells, stress, metabolism and cancer: a drama in two Octs. Trends Biochem Sci 34: 491-499.
57. Phillips K, Luisi B, (2000) The virtuoso of versatility: POU proteins that flex to fit. J Mol Biol 302: 1023-1039.
58. Ryan AK, Rosenfeld MG, (1997) POU domain family values: flexibility, partnerships, and developmental codes. Genes Dev 11: 1207-1225.
59. Carroll KD, Khadim F, Spadavecchia S, Palmeri D, Lukac DM, (2007) Direct interactions of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50/Rta protein with the cellular protein octamer-1 and DNA are critical for specifying transactivation of a delayed-early promoter and stimulating viral reactivation. J Virol 81: 8451-8467.
60. Sakakibara S, Ueda K, Chen J, Okuno T, Yamanishi K, (2001) Octamer-binding sequence is a key element for the autoregulation of Kaposi's sarcoma-associated herpesvirus ORF50/Lyta gene expression. J Virol 75: 6894-6900.
61. Herr W, (1998) The herpes simplex virus VP16-induced complex: mechanisms of combinatorial transcriptional regulation. Cold Spring Harb Symp Quant Biol 63: 599-607.
62. Wysocka J, Herr W, (2003) The herpes simplex virus VP16-induced complex: the makings of a regulatory switch. Trends Biochem Sci 28: 294-304.
63. Kristie TM, Sharp PA, (1990) Interactions of the Oct-1 POU subdomains with specific DNA sequences and with the HSV alpha-trans-activator protein. Genes Dev 4: 2383-2396.
64. Kristie TM, Sharp PA, (1993) Purification of the cellular C1 factor required for the stable recognition of the Oct-1 homeodomain by the herpes simplex virus alpha-trans-induction factor (VP16). J Biol Chem 268: 6525-6534.
65. Moriuchi H, Moriuchi M, Cohen JI, (1995) Proteins and cis-acting elements associated with transactivation of the varicella-zoster virus (VZV) immediate-early gene 62 promoter by VZV open reading frame 10 protein. J Virol 69: 4693-4701.
66. Latchman DS, (1996) The Oct-2 transcription factor. Int J Biochem Cell Biol 28: 1081-1083.
67. Staudt LM, Singh H, Sen R, Wirth T, Sharp PA, et al. (1986) A lymphoid-specific protein binding to the octamer motif of immunoglobulin genes. Nature 323: 640-643.
68. Clerc RG, Corcoran LM, LeBowitz JH, Baltimore D, Sharp PA, (1988) The B-cell-specific Oct-2 protein contains POU box- and homeo box-type domains. Genes Dev 2: 1570-1581.
69. Staudt LM, Clerc RG, Singh H, LeBowitz JH, Sharp PA, et al. (1988) Cloning of a lymphoid-specific cDNA encoding a protein binding the regulatory octamer DNA motif. Science 241: 577-580.
70. Di Bartolo DL, Hyjek E, Keller S, Guasparri I, Deng H, et al. (2009) Role of defective Oct-2 and OCA-B expression in immunoglobulin production and Kaposi's sarcoma-associated herpesvirus lytic reactivation in primary effusion lymphoma. J Virol 83: 4308-4315.
71. Lillycrop KA, Howard MK, Estridge JK, Latchman DS, (1994) Inhibition of herpes simplex virus infection by ectopic expression of neuronal splice variants of the Oct-2 transcription factor. Nucleic Acids Res 22: 815-820.
72. Almqvist J, Zou J, Linderson Y, Borestrom C, Altiok E, et al. (2005) Functional interaction of Oct transcription factors with the family of repeats in Epstein-Barr virus oriP. J Gen Virol 86: 1261-1267.
73. Cepek KL, Chasman DI, Sharp PA, (1996) Sequence-specific DNA binding of the B-cell-specific coactivator OCA-B. Genes Dev 10: 2079-2088.
74. Malin S, Linderson Y, Almqvist J, Ernberg I, Tallone T, et al. (2005) DNA-dependent conversion of Oct-1 and Oct-2 into transcriptional repressors by Groucho/TLE. Nucleic Acids Res 33: 4618-4625.
75. Werner M, Ernberg I, Zou J, Almqvist J, Aurell E, (2007) Epstein-Barr virus latency switch in human B cells: a physico-chemical model. BMC Syst Biol 1: 40.
76. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, et al. (2002) Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B-cell gene expression program. Immunity 17: 51-62.
77. Chang YN, Dong DL, Hayward GS, Hayward SD, (1990) The Epstein-Barr virus Zta transactivator: a member of the bZIP family with unique DNA-binding specificity and a dimerization domain that lacks the characteristic heptad leucine zipper motif. J Virol 64: 3358-3369.
78. Lieberman PM, Berk AJ, (1990) In vitro transcriptional activation, dimerization, and DNA-binding specificity of the Epstein-Barr virus Zta protein. J Virol 64: 2560-2568.
79. Packham G, Economou A, Rooney CM, Rowe DT, Farrell PJ, (1990) Structure and function of the Epstein-Barr virus BZLF1 protein. J Virol 64: 2110-2116.
80. Deng Z, Chen CJ, Zerby D, Delecluse HJ, Lieberman PM, (2001) Identification of acidic and aromatic residues in the Zta activation domain essential for Epstein-Barr virus reactivation. J Virol 75: 10334-10347.
81. Flemington EK, Borras AM, Lytle JP, Speck SH, (1992) Characterization of the Epstein-Barr virus BZLF1 protein transactivation domain. J Virol 66: 922-929.
82. Botfield MC, Jancso A, Weiss MA, (1994) Mapping critical residues in eukaryotic DNA-binding proteins: a plasmid-based genetic selection strategy with application to the Oct-2 POU motif. Biochemistry 33: 6177-6185.
83. Yuan J, Cahir-McFarland E, Zhao B, Kieff E, (2006) Virus and cell RNAs expressed during Epstein-Barr virus replication. J Virol 80: 2548-2565.
84. Yu F, Feng J, Harada JN, Chanda SK, Kenney SC, et al. (2007) B-cell terminal differentiation factor XBP-1 induces reactivation of Kaposi's sarcoma-associated herpesvirus. FEBS Lett 581: 3485-3488.
85. Tanaka M, Herr W, (1990) Differential transcriptional activation by Oct-1 and Oct-2: interdependent activation domains induce Oct-2 phosphorylation. Cell 60: 375-386.
86. Heckman KL, Pease LR, (2007) Gene splicing and mutagenesis by PCR-driven overlap extension. Nat Protoc 2: 924-932.
87. Rhee JM, Trieu M, Turner EE, (2001) Optimal Oct-2 affinity for an extended DNA site and the effect of GST fusion on site preference. Arch Biochem Biophys 385: 397-405.
88. Bhende PM, Seaman WT, Delecluse HJ, Kenney SC, (2005) BZLF1 activation of the methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186. J Virol 79: 7338-7348.
89. Grässer FA, Murray PG, Kremmer E, Klein K, Remberger K, et al. (1994) Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood 84: 3792-3798.
90. Hong GK, Delecluse HJ, Gruffat H, Morrison TE, Feng WH, et al. (2004) The BRRF1 early gene of Epstein-Barr virus encodes a transcription factor that enhances induction of lytic infection by BRLF1. J Virol 78: 4983-4992.
91. Gorman CM, Moffat LF, Howard BH, (1982) Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 2: 1044-1051.
92. Suárez Y, Fernández-Hernando C, Pober JS, Sessa WC, (2007) Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 100: 1164-1173.
93. Chugh P, Tamburro K, Dittmer DP, (2010) Profiling of pre-micro RNAs and microRNAs using quantitative real-time PCR (qPCR) arrays. J Vis Exp 46: pii. 2210 doi:10.379/2210.
94. Papin J, Vahrson W, Hines-Boykin R, Dittmer DP, (2005) Real-time quantitative PCR analysis of viral transcription. Methods Mol Biol 292: 449-480.